News

Trial of namilumab for pulmonary sarcoidosis now fully enrolled

The Phase 2 clinical trial RESOLVE-Lung, which is testing namilumab as a treatment for people with chronic pulmonary sarcoidosis, is now fully enrolled. According to Kinevant Sciences, the therapy’s developer, 107 patients with hard-to-treat pulmonary sarcoidosis — disease that’s “not well-controlled despite currently available treatment” — have been…

Walgreens, FSR unite in Alabama for Sarcoidosis Awareness Month

Walgreens and the Foundation for Sarcoidosis Research (FSR) have renewed their partnership to raise awareness about sarcoidosis and the importance of spring respiratory vaccines, as part of this April’s Sarcoidosis Awareness Month. Until the end of the month, all Alabama-based Walgreens stores will provide informational resources to…